Gapping up
In reaction to strong earnings/guidance: ORIG +15.9%, PLCE +8.7%, DRYS +5.5%, ENZ +1.8%
M&A news: FCS +7.8% (acknowledges receipt of an unsolicited proposal to be acquired for $21.70/share in cash, says Board will review and consider the proposal)
Other news: ONTX +43.5% (presents positive data from Phase 2 combination trial of oral Rigosertib and Azacitidine), TXMD +38.7% (announced positive top-line results from its pivotal Phase 3 Rejoice Trial of TX-004HR), ANAD +17.6% (announced end of 'go-shop period'), GLPG +17.4% (announced that its 200 mg filgotinib product has been shown to be effective and safe as once-daily, oral induction treatment in moderate to severe Crohn's disease), PIRS +16.5% (announces research collaboration and license agreement with Roche (RHHBY) in cancer immunotherapy), EFUT +9.5% ( raises active stake to 56.49% (Prior 50.51%)), ICLD +7.8% (commences a review of its strategic alternatives in response to the receipt of multiple unsolicited offers to purchase certain of its key assets), BSI +7.7% (announced that Mega Retail has agreed to sell six supermarket branches to Rami Levi Chain Stores Hashikma Marketing; consideration will be NIS 26 mln), CUR +7.5% reports that NSI-189 molecule data has been published in Molecular Psychiatry), CPXX +7.3% (reports positive data for Vyxeos, showing induced high rates of response in patients with AML), CTRV +6.8% (reports positive results for CMX157; results from head-to-head studies support CMX157's), ZIOP +5% (announced presentation of data from CD19-specific car+ T-cell therapy programs; results demonstrate survival benefit in long-term follow-up infusing autologous genetically modified T cells after hsct), SYN +4.7% (positive topline results from the four week Phase 2 clinical trial of SYN-010 for the treatment of irritable bowel syndrome with constipation), GALE +2.6% (reports final data for its GALE-401 Phase 2 proof-of-concept clinical trial), CSRA +1.8% (awarded an IDIQ contract from the Dept of Homeland Security for support of its Data Center 1), EGRX+1.7% (Eagle Pharma and Teva Pharma announce that the FDA has approved BENDEKA), DBVT +1.3% (announced the initiation of a pivotal Phase III study designed to evaluate the safety and efficacy of Viaskin)
Analyst comments: FEYE +3.3% (upgraded to Buy from Neutral at Citigroup), MESO +2.5% (initiated with a Overweight at JP Morgan), ARES +1% (upgraded to Buy from Neutral at BofA/Merrill)
In reaction to strong earnings/guidance: ORIG +15.9%, PLCE +8.7%, DRYS +5.5%, ENZ +1.8%
M&A news: FCS +7.8% (acknowledges receipt of an unsolicited proposal to be acquired for $21.70/share in cash, says Board will review and consider the proposal)
Other news: ONTX +43.5% (presents positive data from Phase 2 combination trial of oral Rigosertib and Azacitidine), TXMD +38.7% (announced positive top-line results from its pivotal Phase 3 Rejoice Trial of TX-004HR), ANAD +17.6% (announced end of 'go-shop period'), GLPG +17.4% (announced that its 200 mg filgotinib product has been shown to be effective and safe as once-daily, oral induction treatment in moderate to severe Crohn's disease), PIRS +16.5% (announces research collaboration and license agreement with Roche (RHHBY) in cancer immunotherapy), EFUT +9.5% ( raises active stake to 56.49% (Prior 50.51%)), ICLD +7.8% (commences a review of its strategic alternatives in response to the receipt of multiple unsolicited offers to purchase certain of its key assets), BSI +7.7% (announced that Mega Retail has agreed to sell six supermarket branches to Rami Levi Chain Stores Hashikma Marketing; consideration will be NIS 26 mln), CUR +7.5% reports that NSI-189 molecule data has been published in Molecular Psychiatry), CPXX +7.3% (reports positive data for Vyxeos, showing induced high rates of response in patients with AML), CTRV +6.8% (reports positive results for CMX157; results from head-to-head studies support CMX157's), ZIOP +5% (announced presentation of data from CD19-specific car+ T-cell therapy programs; results demonstrate survival benefit in long-term follow-up infusing autologous genetically modified T cells after hsct), SYN +4.7% (positive topline results from the four week Phase 2 clinical trial of SYN-010 for the treatment of irritable bowel syndrome with constipation), GALE +2.6% (reports final data for its GALE-401 Phase 2 proof-of-concept clinical trial), CSRA +1.8% (awarded an IDIQ contract from the Dept of Homeland Security for support of its Data Center 1), EGRX+1.7% (Eagle Pharma and Teva Pharma announce that the FDA has approved BENDEKA), DBVT +1.3% (announced the initiation of a pivotal Phase III study designed to evaluate the safety and efficacy of Viaskin)
Analyst comments: FEYE +3.3% (upgraded to Buy from Neutral at Citigroup), MESO +2.5% (initiated with a Overweight at JP Morgan), ARES +1% (upgraded to Buy from Neutral at BofA/Merrill)